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Abstract
Background: HIV infection is associated with increased risk of renal dysfunction, including tubular dysfunction (TD)
related to antiretroviral therapy (ART). Tenofovir disoproxil fumarate (TDF) is becoming available for ART in sub-
Saharan Africa, although data on its long-term safety there is limited. We aimed to study the prevalence of HIV-
associated renal dysfunction in Ghana and explore associations between proteinuria or TD and potential risk factors,
including TDF use.
Methods: A single-centre cross-sectional observational study of patients taking ART was undertaken. Creatinine
clearance (CrCl) was calculated and proteinuria detected with dipsticks. Spot urinary albumin and protein:creatinine
ratios (uACR/uPCR) were measured and further evidence of TD (defined as having two or more characteristic
features) sought. Logistic regression analysis identified factors associated with proteinuria or TD.
Results: In 330 patients, of whom 101 were taking TDF (median 20 months), the prevalence of CrCl < 60ml/min/
1.73m2, dipstick proteinuria and TD was 7 %, 37 % and 15 %. Factors associated with proteinuria were baseline
CD4-count [aOR 0.86/100 cell increment (95 % CI, 0.74–0.99)] and TDF use [aOR 2.74 (95 % CI, 1.38–5.43)]. The only
factor associated with TD was TDF use [aOR 3.43 (95 % CI, 1.10–10.69)]. In a subset with uPCR measurements, uPCRs
were significantly higher in patients taking TDF than those on other drugs (10.8 vs. 5.7 mg/mmol, p < 0.001), and
urinary albuin:protein ratios significantly lower (0.24 vs. 0.58, p < 0.001).
Conclusions: Both proteinuria and TD are common and associated with TDF use in Ghana. Further longitudinal
studies to determine whether proteinuria, TD or TDF use are linked to progressive decline in renal function or other
adverse outcomes are needed in Africa.
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Background
HIV-infected individuals are at increased risk of renal
dysfunction due to a number of causes including
HIV-associated nephropathy (HIVAN), HIV immune
complex glomerulonephritis and antiretroviral therapy
(ART) [1–4]. The use of ART has decreased HIV-
associated renal dysfunction and progression to end
stage renal disease (ESRD) [5–8], but renal dysfunc-
tion remains common amongst HIV-infected patients.
There is a higher prevalence of renal dysfunction and
ESRD among the African-American population (largely of
West African descent) compared to Caucasians [9–11].
Genetic polymorphisms [12], higher prevalence of dia-
betes mellitus and hypertension, and other co-morbidities
including hepatitis B virus (HBV), schistosomiasis and
malaria infections ensure that renal dysfunction is com-
mon in West Africans regardless of HIV status. HIVAN is
the most common HIV-related renal pathology in sub
Saharan Africa [13, 14]. It appears that the prevalence of
HIV-related renal dysfunction, defined by estimated glom-
erular filtration rate (eGFR) <60 ml/min, may be higher
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among ART-naïve West Africans compared with those
from East and Southern Africa [7, 13, 15–19].
The nucleotide reverse transcriptase inhibitor tenofo-
vir disoproxil fumarate (TDF), which is active against
HBV in addition to HIV, is now widely used in Africa.
TDF is excreted through a combination of glomerular
filtration and active tubular secretion, with uptake in the
proximal tubule and secretion into the tubular space
[20]. Initial clinical trials described a favourable renal
safety profile [21, 22], however there were rare post-
marketing reports of Fanconi’s syndrome (proximal
tubulopathy) leading to glucosuria, phosphaturia, amino-
aciduria and bicarbonate wasting [23, 24]. Subsequent
studies have found that TDF use causes a small but sig-
nificant decrease in creatinine clearance (a surrogate for
glomerular filtration) in both HIV positive and negative
populations [25, 26]. There has been increasing interest
in TDF-associated tubular dysfunction (TD), the dur-
ation of TDF exposure appearing to play a part, with cu-
mulative TDF exposure associated with increased risk of
proximal TD in adults [27–30]. Genetic polymorphisms
may cause a predisposition for TDF associated TD [20].
Little is known about the prevalence of TD in Africa as
it is difficult to screen for this complication in resource-
poor areas, and few African studies have investigated
markers of TD. We therefore undertook this study to
determine the prevalence of renal dysfunction including
TD in HIV-infected individuals taking ART in Ghana
and examine potential associated risk factors including
TDF exposure.
Methods
This was an observational cross-sectional single-centre
study involving HIV-infected patients taking ART. This
study was conducted at the Komfo Anokye Teaching Hos-
pital (KATH) in Kumasi, Ghana. The Committee on Hu-
man Research Publications and Ethics at KATH approved
the study. Patients were initiated on either zidovudine or
stavudine with lamivudine, plus either nevirapine or efavir-
enz prior to 2010 when TDF became available. After this a
small proportion of patients, included those identified with
hepatitis B co-infection, were initiated on (or switched to)
TDF. All patients ≥18 years old attending the HIV clinic
who had been taking ART for at least 6 months and who
gave informed consent during the study period were
screened for renal dysfunction by urine dipsticks and serum
creatinine. Demographic, medical and laboratory data was
collected from case notes. Individuals with known causes of
renal impairment or urinary tract infections (positive dip-
stick for leukocytes and nitrites), were excluded. Patients
with ‘one plus’ or more of protein or glucose on dipsticks
were considered positive for proteinuria or glycosuria, the
latter only if a blood glucose was <9 mmol/L. To further
define the level and characteristics of proteinuria in a
(randomly-selected) subset of individuals with proteinuria,
spot urine protein:creatinine (uPCR), urine albumin:creati-
nine (uACR) and urinary albumin:protein (uAPR) ratios
were calculated. Creatinine clearance (CrCl) was calculated
using the Cockroft-Gault equation, based on local practice
patterns.
In a subset of patients – all those who had suffi-
cient volumes of urine and blood specimens - frac-
tional phosphate and urate excretion was measured,
in addition to glycosuria and uAPR, to identify TD.
TD was defined as having two or more of the follow-
ing: fractional phosphate excretion >18 %, fractional
urate excretion >15 %, normo-glycaemic glycosuria,
proteinuria (uPCR > 20 mg/mmol) with uAPR < 0.4.
Descriptive results of continuous variables were
expressed as medians and interquartile ranges. Con-
tinuous variables were compared using Student’s t test
or Wilcoxon rank sum test, as required. For the com-
parison of proportions, the Chi-squared test was used,
with Fisher’s corrections applied when needed. Uni-
variate and multivariate logistic regression analyses
were performed to identify factors associated with
proteinuria or TD. Parameters with p < 0.1 in the uni-
variate analysis were entered into a stepwise multi-
variate analysis. All statistics were conducted using
SAS, version 9.3.
Results
In total, 367 patients were screened for evidence of renal
dysfunction with urine dipsticks and blood creatinine
measurement, and 37 excluded due to evidence of urinary
tract infection or other causes of renal impairment, in-
cluding diabetes and hypertension. Of the 330 remaining,
who had been taking ART for a median of 24 (IQR 15–48)
months, 101 were taking TDF for a median of 20 (12–14)
months, with the remainder taking either stavudine or zi-
dovudine with lamivudine. The characteristics of this
population are shown in Table 1. Demographic character-
istics were similar amongst patient taking or not taking
TDF. Proteinuria was common, found in 37 % of the en-
tire cohort, and confirmed in 20/167 (12 %) patients with
uPCRs >20 mg/mmol. 7 % of patients had CrCl <60 ml/
min/1.73m2. TD was found in 12 of 82 (15 %) patients
who were evaluated. Patients on TDF were more likely to
be HBV co-infected (HBsAg+), have glycosuria and pro-
teinuria on dipsticks, had significantly higher uPCRs (10.8
vs 5.7 mg/mmol, p < 0.001) and lower uAPRs (0.24 vs
0.58, p < 0.001), with 35 % of those on TDF (vs. 6 % not
on TDF) satisfying the criteria for TD.
Univariate and multivariate analyses of factors associated
with dipstick proteinuria (in the entire population) and TD
(in a subset of 82 patients) are shown in Table 2. Younger
age and lower baseline CD4 count were marginally associ-
ated with proteinuria, odds ratio (OR) 0.77 (95 % CI, 0.59–
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1.00) and 0.88 (0.77–1.01) respectively, as was TDF use, OR
1.82 (1.12–2.95). Factors independently associated with
proteinuria were lower baseline CD4 count, adjusted odds
ratio (aOR) 0.86 per 100 cell increment (0.74–0.99), and
TDF use, aOR 2.74 (1.38–5.43). In a sensitivity analysis, use
of TDF was significantly associated with proteinuria, un-
adjusted OR of 3.56 (1.21-10.50), p = 0.02, where only pa-
tients with confirmed uPCR > 20 (not dipstick-only
proteinuria) were included. Similar results were also found
where only patients with dipstick proteinuria >1+ were in-
cluded. Although lower age was associated with TD in uni-
variate analysis, the only factor associated with TD in both
univariate and multivariate analyses was TDF use, aOR 3.43
(1.10–10.69). Of note, duration of TDF therapy was not sig-
nificantly associated with odds of proteinuria, uPCR, or
TD.
Discussion
Previous studies of populations taking TDF, including
some in Africa, have shown that significant declines
in renal function are rare [7, 31, 32]. However only
the DART study, based in East and Southern Africa,
has followed patients beyond 2 years [29], and to our
knowledge no studies have assessed TD in addition to
declines in estimated glomerular filtration rates
(eGFR)/CrCl or proteinuria in Africa. We postulated
that proteinuria may be more frequent in West
Africans taking ART due to a genetic predisposition
and other factors such as HBV co-infection, which is
common in Ghana [33] and has been associated with
renal dysfunction in HIV-infected patients [34]. We
also postulated that the phasing out of stavudine and
zidovudine in the Ghana ART programme, and their
gradual replacement with TDF from 2010, might lead
to an increase in TD in patients on TDF-based ART.
Our study has shown strong evidence of both TD and
proteinuria being associated with TDF use. It has also
demonstrated that whilst CrCl < 60mls/min is rela-
tively rare in this population, TD is common (found
in 15 % of all patients and 35 % of those on TDF) as
is proteinuria, which was found in over one third of
the population studied. Cross-sectional studies in
European populations have identified between 7–22 % of
patients on ART having evidence of TD [20, 28–30], using
different definitions of TD, which is similar to the overall
rate found in Ghana however lower than that found in pa-
tients taking TDF. Given that use of protease inhibitors
has also been associated with TD, since no patients receiv-
ing protease inhibitors had features of TD, it is likely most
ART-related TD was due to TDF alone [29, 35]. As in
other studies, very few of the patients meeting our defin-
ition of TD had evidence of clinically-significant TD or
Fanconi syndrome, and the long-term significance of this
finding is uncertain.
Table 1 Characteristics of the study population
Taking TDF Not taking TDF All patients p
(n = 101) (n = 229) (n = 330)
Female, No. (%) 82 (81) 165 (72) 247 (75) 0.08
Age, Median (IQR), years 38 (34–46) 40 (36–46) 39 (35–46) 0.09
BMI, Median (IQR), kg/m2 22.8 (21.5–25.3) 22.9 (20.3–27.1) 22.9 (20.5-26.6) 0.11
Nadir CD4 Median (IQR), cells/μl 164 (94–265) 186 (76–297) 185 (79–297) 0.79
Current CD4 Median (IQR), cells/μl 545 (337–679) 456 (335–630) 463 (329–640) 0.22
CrCld, Median (IQR), ml/min/1.73m2 99 (78–118) 96 (77–126) 95 (77–118) 0.21
CrCl < 60 ml/min/1.73 m2, No (%) 5 (5) 19 (8) 24 (7) 0.28
Efavirenz-based ART, No. (%)b 71 (70) 147 (64) 218 (66) 0.28
Duration on tenofovir, Median (IQR), months 20 (12–24)
HBsAg positivea, No. (%) 20/56 (36) 8/101 (8) 28/157 (18) 0.0004
Proteinuria (dipstick), No. (%) 62 (61) 73 (32) 123 (37) <0.0001
uPCRb, Median (IQR), mg/mmol 10.8 (6.8–15.1) 5.7 (3.3–10.4) 7.7 (5.2–12.9) <0.0001
uACRb, Median (IQR), mg/mmol 2 (0.58–2.4) 2.1 (1.0–4.6) 2 (0.7–3.4) 0
uAPRe, Median (IQR), mg 0.24 (0.1–0.4) 0.58 (0.4–0.6) 0.43 (0.2–0.6) 0.0006
Fractional phosphate excretion > 18 %d, No. (%) 2/28 (7) 6/54 (11) 8/82 (10) 0.57
Fractional urate excretion > 15 %d, No. (%) 1/28 (4) 4/54 (7) 5/82 (6) 0.49
Glycosuria (dipstick), No. (%) 24 (24) 5 (2) 29 (9) <0.0001
TDF tenofovir disoproxil fumarate, BMI body mass index, CrCl estimated creatinine clearance (by Cockcroft Gault formula), uPCR urinary protein:creatinine ratio,
uACR urinary albumin:creatinine ratio, uAPR urinary albumin:protein ratio. aHBsAg hepatitis B surface antigen (based on a subset of 157 patients)
bBased on subset of 161 patients. cMost other patient were taking nevirapine. d Based on subset of 82 patients
eWhere uPCR > 20 mg/mmol
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Hardly any studies outside Africa have identified such a
high proportion of ART-treated patients having proteinuria
as ours. High rates of proteinuria have been noted in two
other studies in Africa, however neither study distinguished
the type of proteinuria in terms of albumin and total pro-
tein [12, 36]. This study demonstrated that in patients with
significant proteinuria, those taking TDF had a lower albu-
min:protein ratios which is characteristic of tubular rather
than glomerular dysfunction [37], indicating that HIVAN
was probably not the predominant pathology causing renal
dysfunction. Interestingly, lower age was associated with
proteinuria in our study, in contrast to older age being
more often associated with proteinuria, although this might
be explained by orthostatic proteinuria which is common
in young adults. Given increasing evidence that an alterna-
tive form of tenofovir, tenofovir alafenamide (TAF), is less
nephrotoxic than TDF [38], and is likely to replace TDF
over the next decade, it is perhaps less likely that significant
numbers of patients will develop TDF-associated renal dys-
function or chronic kidney disease (CKD).
Limitations of this study include the relatively small sam-
ple of patients who were tested for features of TD and num-
bers who had available HBV serology, limiting the power of
the analyses to demonstrate correlations of postulated risk
factors with TD. Given the strong association between TDF
use and HBsAg + status, this may also have introduced con-
founding by indication. Furthermore, the prevalence of pro-
teinuria and TD may have been over-estimated given that
this was a cross-sectional study without repeated measure-
ment, and in just over half of patients proteinuria was not
confirmed or quantified by measuring uPCR.
Conclusions
In summary this study has shown that both TD and pro-
teinuria are common amongst Ghanaians taking ART,
and TDF use is independently associated with both of
these outcomes. Further studies are needed assessing
clinical outcomes including decline in eGRF/CrCl and
mortality in this population to evaluate the clinical sig-
nificance of these findings.
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Table 2 Predictors of proteinuria and tubular dysfunction in HIV-infected Ghanaians
Variable Proteinuria Tubular dysfunction
OR (95 % CI) p aOR (95 % CI) p OR (95 % CI) p aOR (95 % CI) p
Age/10 years 0.77 (0.59–1.00) 0.05 0.74 (0.54–1.01) 0.06 0.58 (0.35–0.98) 0.04 0.62 (0.36–1.06) 0.08
Baseline CD4/100 cells/mm3 0.88 (0.77–1.01) 0.07 0.86 (0.74–0.99) 0.04 1.11 (0.88–1.40) 0.38
Gender
Female 1.05 (0.63–1.78) 0.84 0.96 (0.35–2.61) 0.93
Male 1 1
BMI /5 kg/m2 0.88 (0.69–1.12) 0.29 0.83 (0.50–1.38) 0.47
Each year on ART 0.95 (0.84–1.07) 0.38 0.92 (0.69–1.21) 0.53
Use of TDF
Yes 1.82 (1.12–2.95) 0.01 2.74 (1.38–5.43) 0.004 3.83 (1.24–11.77) 0.02 3.43 (1.10–10.69) 0.03
No 1 1 1 1
Current CD4/100 cells/mm3 0.98 (0.89–1.08) 0.65 1.09 (0.93–1.29) 0.29
Duration on TDF/1yr 1.00 (0.97–1.03) 0.86 1.13 (0.73–1.76) 0.57
HBV Serology
HBsAg + 0.81 (0.36–1.85) 0.62 1.93 (0.49–7.56) 0.34
HBsAg - 1 1
OR odds ratio, aOR adjusted odds ratio, TDF tenofovir disoproxil fumarate, BMI body mass index, ART antiretroviral therapy, HBV hepatitis B virus
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